SOLNATIDE partners
APEPTICO Forschung und Entwicklung GmbH (APEPTICO) is a private Austrian biotechnology company with headquarters in Vienna. APEPTICO develops peptide-based products targeting chronic and life-threatening diseases with peptide molecules having synthetically produced protein structures to avoid risks associated with commonly used gene and cell technologies.
One of these developments is the therapeutic peptide solnatide, which is being investigated in the H2020-funded SOLNATIDE project.

What we do for the SOLNATIDE project
APEPTICO is the Scientific Coordinator of the SOLNATIDE project and the main clinical study sponsor.
Moreover, we are the work package leaders of WP5 (Solnatide IMP Formulation & Manufacture) and mainly involved in WP1 (Ethical Requirements).
CEO of APEPTICO, Bernhard Fischer
“We are very proud to work together with the consortium of the SOLNATIDE project for the development of an innovative medicine for the treatment of severe CODID-19 patients.”
RTDS Group (RTDS) is an EU funding consultancy and service company based in Vienna and specialises in Horizon 2020/Horizon Europe proposal preparation, setting up of grant and consortium agreements, and subsequently, project implementation. Not pursuing ownership of core research results, RTDS objectively supports the consortium in project administration and management of results to ensure agreement on exploitation of results to achieve the highest possible impact.

In project implementation, the RTDS role often begins with organisation of the kick-off meeting, introducing the administrative measures, then setting up the website and social media channels to publicly announce the project. During the project, RTDS is responsible for management of results (i.e. ascertaining result ownership, TRL assessment, developing IP protection strategies and business models together with the partners).
To ensure stakeholders are informed and to promote uptake of the results, RTDS develops and implements tailored dissemination and communication plans and measures including animation and video clip production, social media campaigns, support with open access publishing and (online) events and conferences.

RTDS as the Project Coordinator of SOLNATIDE is responsible for the overall project management as well as for all tasks related to communication and dissemination (WP6). Moreover, RTDS is the work package leader of WP1 (Ethical Requirements).
“RTDS is proud to support APEPTICO and the SOLNATIDE consortium in their effort to ascertain the efficacy of the solitude peptide to treat COVID-19 patients. #UnitedAgainstCoronavirus #StrongerTogether.”
BCN Peptides (BCN) is a privately owned Spanish company located near Barcelona whose main focus is manufacturing bioactive peptides for pharmaceutical and veterinary applications. The BCN scientific team provides excellent expertise on synthetic peptide chemistry and analytics, especially on long sequences and cyclic peptides for manufacturing generic as well as custom peptides.
Certainly, BCN has an excellent GMP compliance track record with all major institutions (e.g. FDA, EDQM, PMPDA, etc.) for its state-of-the-art facility.

What we do for the SOLNATIDE project
BCN is leading WP4 (Solnatide API Manufacture & Characterisation) and will manufacture the solnatide active pharmaceutical ingredient for the project.
BCN Sales Manager Jordi Piró on SOLNATIDE
“We are committed to improve the health of the people, so we are very proud and excited about the opportunity of collaborating with APEPTICO and the SOLNATIDE consortium to bring medicine to the market that saves lives, especially severely ill COVID-19 patients.”
The Department of Anaesthesiology is part of the University Clinic of the Ludwig-Maximilians-University Munich (LMU).
Our department focuses on operative anaesthesiology, pain therapy as well as general and specific intensive care medicine, e.g. after transplantations or in patients with severe lung failure. Besides, research as well as teaching are main pillars of the clinic.
During the 2020 Coronavirus pandemic, we are responsible for treating severe cases of the infection from the greater Munich and other southern German areas in our intensive care units (ICU).



What we do for the SOLNATIDE project
The LMU hospital is leading WP3 (Treatment of Patients with ARDS) and deciding on inclusion of patients in our double-blind clinical study.
Principal investigator and intensivist, Sandra Frank, on SOLNATIDE
”Since treating the first COVID-19 positive patient we gained a lot of new insight into this new and challenging disease. We are thankful for every new therapeutic approach as every day we learn more about how to effectively treat and cure our often severely ill patients.”
Founded in 1998 in Italy and now operating internationally, OPIS is a Contract Research Organization (CRO) providing full-service premium trial management for multi-country clinical trials. This includes state-of-the-art information technology solutions and innovative approaches to tackle the increasing complexity and variety of projects.
OPIS extensive expertise covers all phases of drug related trials, with no restrictions to therapeutic area as well as clinical investigations for medical and diagnostic devices, Investigator Initiated Trials (IITs), and compassionate use programs. The OPIS developed EDC solution Clinical.net is FDA-compliant and fully customizable to digitally manage all clinical trial data.

OPIS is the Work Package leader of WP2 (Clinical Trial Management) with the main objective of WP2 being the set up and running of the SOLNATIDE COVID-19 clinical trials.
OPIS is responsible for the regulatory set-up and management of the clinical activities. They oversee the communication with regulatory authorities and clinical sites, as well as site management, site monitoring, and visits.
OPIS manages the data management including handing of CRF (Case Report Forms). Moreover, is also responsible for the pharmacovigilance process. OPIS is also in charge of data management, especially of the study-related data in collaboration with its Data Protection Officer (DPO).
For SOLNATIDE, the Italian as well as the German OPIS branches provide their expertise to the project.

Aldo Poli, CEO of OPIS, on SOLNATIDE
“We are proud to participate to the clinical development of solnatide in patient affected with COVID-19. At this time of great difficulty on a global level, OPIS is pleased to be at the forefront of the fight against coronavirus, collaborating with the consortium with the aim of providing a new therapeutic approach in patients with COVID-19 who develop respiratory complications.”
APEPTICO Forschung und Entwicklung GmbH (APEPTICO) is a private Austrian biotechnology company with headquarters in Vienna. APEPTICO develops peptide-based products targeting chronic and life-threatening diseases with peptide molecules having synthetically produced protein structures to avoid risks associated with commonly used gene and cell technologies.
One of these developments is the therapeutic peptide solnatide, which is being investigated in the H2020-funded SOLNATIDE project.

What we do for the SOLNATIDE project
APEPTICO is the Scientific Coordinator of the SOLNATIDE project and the main clinical study sponsor.
Moreover, we are the work package leaders of WP5 (Solnatide IMP Formulation & Manufacture) and mainly involved in WP1 (Ethical Requirements).
CEO of APEPTICO, Bernhard Fischer
“We are very proud to work together with the consortium of the SOLNATIDE project for the development of an innovative medicine for the treatment of severe CODID-19 patients.”
BCN Peptides (BCN) is a privately owned Spanish company located near Barcelona whose main focus is manufacturing bioactive peptides for pharmaceutical and veterinary applications. The BCN scientific team provides excellent expertise on synthetic peptide chemistry and analytics, especially on long sequences and cyclic peptides for manufacturing generic as well as custom peptides.
Certainly, BCN has an excellent GMP compliance track record with all major institutions (e.g. FDA, EDQM, PMPDA, etc.) for its state-of-the-art facility.

What we do for the SOLNATIDE project
BCN is leading WP4 (Solnatide API Manufacture & Characterisation) and will manufacture the solnatide active pharmaceutical ingredient for the project.
BCN Sales Manager Jordi Piró on SOLNATIDE
“We are committed to improve the health of the people, so we are very proud and excited about the opportunity of collaborating with APEPTICO and the SOLNATIDE consortium to bring medicine to the market that saves lives, especially severely ill COVID-19 patients.”
The Department of Anaesthesiology is part of the University Clinic of the Ludwig-Maximilians-University Munich (LMU).
Our department focuses on operative anaesthesiology, pain therapy as well as general and specific intensive care medicine, e.g. after transplantations or in patients with severe lung failure. Besides, research as well as teaching are main pillars of the clinic.
During the 2020 Coronavirus pandemic, we are responsible for treating severe cases of the infection from the greater Munich and other southern German areas in our intensive care units (ICU).



What we do for the SOLNATIDE project
The LMU hospital is leading WP3 (Treatment of Patients with ARDS) and deciding on inclusion of patients in our double-blind clinical study.
Principal investigator and intensivist, Sandra Frank, on SOLNATIDE
”Since treating the first COVID-19 positive patient we gained a lot of new insight into this new and challenging disease. We are thankful for every new therapeutic approach as every day we learn more about how to effectively treat and cure our often severely ill patients.”
RTDS Group (RTDS) is an EU funding consultancy and service company based in Vienna and specialises in Horizon 2020/Horizon Europe proposal preparation, setting up of grant and consortium agreements, and subsequently, project implementation. Not pursuing ownership of core research results, RTDS objectively supports the consortium in project administration and management of results to ensure agreement on exploitation of results to achieve the highest possible impact.

In project implementation, the RTDS role often begins with organisation of the kick-off meeting, introducing the administrative measures, then setting up the website and social media channels to publicly announce the project. During the project, RTDS is responsible for management of results (i.e. ascertaining result ownership, TRL assessment, developing IP protection strategies and business models together with the partners).
To ensure stakeholders are informed and to promote uptake of the results, RTDS develops and implements tailored dissemination and communication plans and measures including animation and video clip production, social media campaigns, support with open access publishing and (online) events and conferences.

RTDS as the Project Coordinator of SOLNATIDE is responsible for the overall project management as well as for all tasks related to communication and dissemination (WP6). Moreover, RTDS is the work package leader of WP1 (Ethical Requirements).
“RTDS is proud to support APEPTICO and the SOLNATIDE consortium in their effort to ascertain the efficacy of the solitude peptide to treat COVID-19 patients. #UnitedAgainstCoronavirus #StrongerTogether.”
Founded in 1998 in Italy and now operating internationally, OPIS is a Contract Research Organization (CRO) providing full-service premium trial management for multi-country clinical trials. This includes state-of-the-art information technology solutions and innovative approaches to tackle the increasing complexity and variety of projects.
OPIS extensive expertise covers all phases of drug related trials, with no restrictions to therapeutic area as well as clinical investigations for medical and diagnostic devices, Investigator Initiated Trials (IITs), and compassionate use programs. The OPIS developed EDC solution Clinical.net is FDA-compliant and fully customizable to digitally manage all clinical trial data.

OPIS is the Work Package leader of WP2 (Clinical Trial Management) with the main objective of WP2 being the set up and running of the SOLNATIDE COVID-19 clinical trials.
OPIS is responsible for the regulatory set-up and management of the clinical activities. They oversee the communication with regulatory authorities and clinical sites, as well as site management, site monitoring, and visits.
OPIS manages the data management including handing of CRF (Case Report Forms). Moreover, is also responsible for the pharmacovigilance process. OPIS is also in charge of data management, especially of the study-related data in collaboration with its Data Protection Officer (DPO).
For SOLNATIDE, the Italian as well as the German OPIS branches provide their expertise to the project.

Aldo Poli, CEO of OPIS, on SOLNATIDE
“We are proud to participate to the clinical development of solnatide in patient affected with COVID-19. At this time of great difficulty on a global level, OPIS is pleased to be at the forefront of the fight against coronavirus, collaborating with the consortium with the aim of providing a new therapeutic approach in patients with COVID-19 who develop respiratory complications.”
RTDS Group (RTDS) is an EU funding consultancy and service company based in Vienna and specialises in Horizon 2020/Horizon Europe proposal preparation, setting up of grant and consortium agreements, and subsequently, project implementation. Not pursuing ownership of core research results, RTDS objectively supports the consortium in project administration and management of results to ensure agreement on exploitation of results to achieve the highest possible impact.

In project implementation, the RTDS role often begins with organisation of the kick-off meeting, introducing the administrative measures, then setting up the website and social media channels to publicly announce the project. During the project, RTDS is responsible for management of results (i.e. ascertaining result ownership, TRL assessment, developing IP protection strategies and business models together with the partners).
To ensure stakeholders are informed and to promote uptake of the results, RTDS develops and implements tailored dissemination and communication plans and measures including animation and video clip production, social media campaigns, support with open access publishing and (online) events and conferences.

RTDS as the Project Coordinator of SOLNATIDE is responsible for the overall project management as well as for all tasks related to communication and dissemination (WP6). Moreover, RTDS is the work package leader of WP1 (Ethical Requirements).
“RTDS is proud to support APEPTICO and the SOLNATIDE consortium in their effort to ascertain the efficacy of the solitude peptide to treat COVID-19 patients. #UnitedAgainstCoronavirus #StrongerTogether.”